Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges

Neurol Clin. 2004 Oct;22(3 Suppl):S63-90. doi: 10.1016/j.ncl.2004.06.008.

Author

Affiliation

¹ Department of Pharmacy Practice, Western University of Health Sciences, 309 East Second Street, Pomona, CA 91766, USA. jchen@westernu.edu

PMID: 15501367
DOI: 10.1016/j.ncl.2004.06.008

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Anti-Anxiety Agents / adverse effects
Anti-Anxiety Agents / therapeutic use
Antidepressive Agents / adverse effects
Antidepressive Agents / therapeutic use
Antiparkinson Agents / adverse effects
Antiparkinson Agents / therapeutic use
Antipsychotic Agents / adverse effects
Antipsychotic Agents / therapeutic use
Anxiety Disorders / diagnosis
Anxiety Disorders / drug therapy
Anxiety Disorders / epidemiology*
Comorbidity
Cross-Sectional Studies
Depressive Disorder / diagnosis
Depressive Disorder / drug therapy
Depressive Disorder / epidemiology*
Drug Interactions
Health Services Needs and Demand / statistics & numerical data*
Humans
Neurocognitive Disorders / diagnosis
Neurocognitive Disorders / drug therapy
Neurocognitive Disorders / epidemiology*
Parkinson Disease / diagnosis
Parkinson Disease / drug therapy
Parkinson Disease / epidemiology*

Substances

Anti-Anxiety Agents
Antidepressive Agents
Antiparkinson Agents
Antipsychotic Agents